Myung-Ju Ahn

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  

Myung-Ju Ahn
Jun 17, 2025, 06:18 | Insight
Aakash Desai Shared A Study Published In JTO on Datopotamab Deruxtecan In Patients With EGFR-mutated NSCLC
Aakash Desai, Assistant Professor and Associate Director of Phase 1 and Precision Oncology Program at…
Jun 13, 2025, 16:39 | Insight
Eric K. Singhi and Jarushka Naidoo Highlighted Study On Pooled Analysis of Datopotamab Deruxtecan in patients with EGFR–mutated NSCLC
Eric K. Singhi, Thoracic Medical Oncologist at MD Anderson Cancer Center, shared a post on…
Jun 6, 2025, 09:57 | Science
Stephen V Liu: Update from the Phase 2 PHAROS Study
Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared a post on X: "Update…
Jun 6, 2025, 07:19 | Opinion
Loay Kassem: 11 Pivotal Trials From ASCO 2025 Published in The NEJM
Loay Kassem, Assistant Professor of Clinical Oncology at Kasr AlAiny School of Medicine, shared a post…
Jun 3, 2025, 12:16 | Drugs
Helena Linardou: Pivotal Paper on Tarlatamab in 2nd Line SCLC by Giannis Mountzios and Colleagues
Helena Linardou, Director of the 4th Oncology Department and the Comprehensive Clinical Trials Center at…
May 1, 2025, 17:14 | Drugs
Ana Velázquez Mañana highlights NEJM study by John Heymach on Zongertinib’s efficacy in HER2-Mutant NSCLC at AACR25
Ana Velázquez Mañana, shared a post on X, about a recent article by John Heymach et…
May 1, 2025, 16:11 | Science
David Planchard Highlights Promise and Access Challenges of HER2-TKIs for HER2-Mutant NSCLC
David Planchard, Thoracic Oncologist, Professor at University Paris Saclay and Head of Thoracic Cancer Group…
Apr 29, 2025, 13:57 | Insight
Rami Manochakian: Zongertinib in Previously Treated HER2-Mutant NSCLC
Rami Manochakian, Vice President of the North American Neuroendocrine Tumor Society, shared an article on…
Mar 18, 2025, 08:51 | Blog
Matt Hellmann: The detection of MRD by assaying ctDNA in patients with cancer
Matt Hellmann, Vice President of Early Oncology Development at AstraZeneca, shared an article Roy S.…
Feb 6, 2025, 15:29 | Blog
Antonio Calles: Cardiotoxicity of osimertinib is real
Antonio Calles, Head of the Lung Cancer Unit at Hospital Ruber Internacional, shared an article…
Jan 12, 2025, 13:43 | Science
Dipesh Uprety: TROPION-Lung05 - a phase II trial on NSCLC by Jacob Sands et al.
Dipesh Uprety, Assistant Professor of Thoracic Oncology at Karmanos Cancer Institute, shared a post on X…
Jan 10, 2025, 17:01 | Insight
Biagio Ricciuti: Datopotamab Deruxtecan in Advanced/Metastatic NSCLC by Jacob Sands et al.
Biagio Ricciuti, Thoracic Medical Oncologist at the Dana-Farber Cancer Institute, shared a post on X about…
Jan 10, 2025, 05:59 | Insight
Results From the Phase II TROPION-Lung05 Study by Jacob Sands et al.
A recent paper by Jacob Sands, Medical Oncologist at Dana-Farber Cancer Institute, was mentioned by…
Jan 8, 2025, 14:07 | Science
Rami Manochakian: Results of TROPION/Lung05 Phase 2 trial are out
Rami Manochakian shared a post on X: "Hot off the press. Just published in the Journal…
Dec 19, 2024, 11:54 | Opinion
Lung Cancer Trial Highlights from 2024 By Yakup Ergün
Yakup Ergün, Medical Oncologist at Antalya City Hospital, posted on X: “What happened in Lung…
Nov 18, 2024, 17:34 | Blog
Evaluating the clinical value of a tumor-naïve, methylation-based cell-free DNA assay in resected NSCLC - IASLC
IASLC posted on X about recent paper by Tae Hee Hong et al., titled "Clinical…
Nov 3, 2024, 13:55 | Insight
Highlights from JLCS24 by Stephen Liu
The 65th Annual Meeting of the Japanese Lung Cancer Society was held at PACIFICO Yokohama…
Oct 20, 2024, 11:34 | Insight
5 papers about lung cancer suggested by Stephen Liu
Stephen Liu, Head of Developmental Therapeutics at Georgetown Lombardi Comprehensive Cancer Center, shared a few…
Oct 13, 2024, 07:07 | Blog
Stephen V Liu: Cardiotoxicity of osimertinib in real world population with EGFR NSCLC
Stephen V Liu shared on X: "Cardiotoxicity of osimertinib in real world population with EGFR…
Sep 26, 2024, 15:35 | Blog
Jarushka Naidoo: TL01 Phase III Datopotamab-Deruxtecan vs Docetaxel in second-line NSCLC
Jarushka Naidoo shared a post on X, about recent paper published in Journal of Clinical…
Sep 18, 2024, 23:22 | Insight
Stephen Liu: Update from TROPION-Lung01
Stephen Liu shared a post on X: “Update from TROPION-Lung01 presented at WCLC24 and now Journal…
Sep 12, 2024, 09:48 | Insight
Datopotamab deruxtecan vs docetaxel for previously treated advanced NSCLC
Erman Akkus shared a post on X about a recent paper by Myung-Ju Ahn et…
Sep 10, 2024, 14:57 | Insight
Article of the day, September 10th, suggested by the Immune Oncology Research Institute
Immune Oncology Research Institute shared a post on LinkedIn: “Article of the day! Suggest by the Immune…
Aug 7, 2024, 16:50 | Blog
The recipients of the 2024 ESMO Society Awards
The 2024 ESMO Society Awards have been announced on 6th August by ESMO. ESMO recently…
Jul 12, 2024, 23:29 | Insight
Clinical Utility of Pre-surgical ctDNA Detection in Early Stage NSCLC
Biagio Ricciuti shared on X: "Clinical Utility of Pre-surgical ctDNA Detection in Early Stage NSCLC…
Jun 26, 2024, 12:05 | Insight
Piotr Wysocki: Osimertinib after radiochemotherapy improves PFS in EGFR-mutated NSCLC patients – but is it really what they need?
Piotr Wysocki recently posted on LinkedIn: "The results of the LAURA study were presented during a…
Jun 10, 2024, 00:53 | Insight
Vijith Shetty: Osimertinib Could Alter SOC for Stage III EGFR+ NSCLC
Vijith Shetty, Associate Professor and Consultant Medical Oncologist at KS Hegde Medical Academy, shared on…
All: 27 Posts: 1 - 100
Special Coverage